ABSTRACT

The ongoing pandemic of COVID-19 has created havoc in the world. With over 190 million COVID-19 cases worldwide, scientists are racing towards developing vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the etiologic agent of COVID- 19. Vaccine elicits both cell-mediated and humoral branches of immunity by the production of effector cells and memory cells, thereby stimulating a strong adaptive response in the vaccinee. Among well over 120 vaccine candidates being scrutinized around the world, some have proven to be very potent in combating SARS-CoV-2. This review presents the outcomes from the pre-clinical studies of mRNA vaccines and killed whole cell vaccines (KWCVs) on suitable animal models, as well as those of Clinical Phase I/II human trials, thereby evaluating their comparative efficacies, emphasizing on the adaptive immune responses developed upon immunization with each of them. Keywords: COVID-19; killed whole cell vaccines (KWCVs); mRNA vaccines; SARS-CoV-2
Publication date: 01/04/2023

https://ijbpas.com/pdf/2023/April/MS_IJBPAS_2023_7077.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.4.7077